

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 February 2025 (20.02.2025)



(10) International Publication Number
WO 2025/037249 A1

(51) International Patent Classification:

C07K 7/64 (2006.01) A61K 51/08 (2006.01)
A61K 38/12 (2006.01) A61P 35/00 (2006.01)
G01N 33/68 (2006.01)

(21) International Application Number:

PCT/IB2024/057866

(22) International Filing Date:

13 August 2024 (13.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/519,599 15 August 2023 (15.08.2023) US
63/650,139 21 May 2024 (21.05.2024) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **BONGARZONE, Salvatore**; ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L., Via dell'industria Prima Traversa, 86077 Pozzilli (ISERNIA) (IT). **CAMPORESE, Davide**; ADVANCED ACCELERATOR APPLICATIONS (ITALY) - S.R.L., Via dell'industria Prima Traversa, 86077 Pozzilli (ISERNIA) (IT). **CLEMENTE, Gonçalo dos Santos**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **EHARA, Takeru**; PEPTIDREAM INC. (also known as PEPTIDREAM K.K.), 3-25-23, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, 210-0821 (JP). **FISCHER, Matteo**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **GOLOSOV, Andrei Alexandrovich**; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **GROSCHKE, Philipp**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **HOLZER, Philipp**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **KARPOV, Alexei**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **LACAUD-BAUMLIN, Marion**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **LEDER, Lukas**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **MALO, Rafael Bermeo**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **MARZINZIK, Andreas**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **MIZUKOSHI, Yoshihide**; PEPTIDREAM INC. (also known as PEPTIDREAM K.K.), 3-25-23, Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, 210-0821 (JP). **MUNSCH, Charlie**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **RESCHKE, Markus Oliver**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **SELLNER, Holger**; Novartis Pharma AG, Lichtstrasse 35, 4056

Basel (CH). **STACHYRA, Therese-Marie**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF

(57) Abstract: Described herein are cyclic peptides targeting fibroblast activation protein (FAP), and their incorporation into compounds for radioligand imaging and therapies, as well as methods and/or uses of such compounds for the imaging, treatment and/or prevention of FAP-implicated diseases and disorders.

WO 2025/037249 A1